GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » Cyclically Adjusted PB Ratio

Ascletis Pharma (HKSE:01672) Cyclically Adjusted PB Ratio : (As of Jun. 04, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma Cyclically Adjusted PB Ratio?

Ascletis Pharma does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascletis Pharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Ascletis Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Cyclically Adjusted PB Ratio Chart

Ascletis Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only - - - - -

Ascletis Pharma Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ascletis Pharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Ascletis Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascletis Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's Cyclically Adjusted PB Ratio falls into.


;
;

Ascletis Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Ascletis Pharma does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.


Ascletis Pharma  (HKSE:01672) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Ascletis Pharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascletis Pharma Business Description

Traded in Other Exchanges
Address
198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other regions.
Executives
Wu Jinzi Jason 2101 Beneficial owner
Wu Judy Hejingdao 2101 Beneficial owner
Jjw12 Limited
Lakemont Holding Llc
Jjw11 Limited
C-bridge Capital Gp, Ltd. 2201 Interest of corporation controlled by you
Fu Wei 2201 Interest of corporation controlled by you
Tf Capital Ii Ltd. 2201 Interest of corporation controlled by you
Tf Capital, Ltd. 2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited 2201 Interest of corporation controlled by you
Yang Dan 2201 Interest of corporation controlled by you

Ascletis Pharma Headlines

No Headlines